Pfizer will pay China’s 3SBio $1.25 billion upfront to gain access to a cancer therapy that could rival Akeso and Summit’s ...

While the clearance is only for use in certain groups, Novavax’s long-awaited OK is still seen by analysts as a “win” for the ...

CEO Keith Gottesdiener will be replaced by Prime's CFO as the company cuts 25% of its workforce and deprioritizes its lead ...

As the NMPA joins the EU and the U.S. in placing sterility assurance and contamination control front and center, ...

The biotech, which has for years invested in genetics research, plans to acquire "substantially all" of testing firm ...

ADARx Pharmaceuticals will work with AbbVie to make RNA interference medicines for a variety of disease areas, including ...

A gene editing drug custom-made for a critically ill baby showed that, for some ultra-rare diseases, it’s possible to design ...

The president claimed his “most-favored nation” proposal would reduce some pharmaceutical prices by as much as 80%, but the ...

Lars Fruergaard Jørgensen will step down after eight years helming the Danish drugmaker, shares of which have shed half their ...

The proposal would see the HHS set price targets other countries pay for certain medicines, kicking off a round of ...

The French drugmaker joined several peers in promising new investments in U.S. drug production, but cautioned plans could ...

The deal “fits like a glove” for BioMarin’s business, according to an analyst who also thinks there could be a “valuable” ...